AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars

ObsEva SA (OBSV) gained 15.09% to close Monday's trading at $12.43. The Company's most advanced investigational drug is OBE2109, under phase III clinical trials for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) in pre-menopausal women, dubbed PRIMROSE 1 and PRIMROSE 2.

from RTT - Biotech http://ift.tt/2DLrAJU
via IFTTT